lonafarnib has been researched along with Acute Lymphoid Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Groffen, J; Heisterkamp, N; Mishra, S; Zhang, B | 1 |
| Daley, GQ; Groffen, J; Heisterkamp, N; Reichert, A | 1 |
2 other study(ies) available for lonafarnib and Acute Lymphoid Leukemia
| Article | Year |
|---|---|
A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Benzamides; Disease Models, Animal; Farnesyltranstransferase; Female; Fusion Proteins, bcr-abl; Imatinib Mesylate; Leukemia, Experimental; Lymphoma; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Nude; Mice, Transgenic; Piperazines; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Survival Rate; Tumor Cells, Cultured | 2004 |
Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Bone Marrow; Farnesyltranstransferase; Genes, abl; Mice; Mice, Transgenic; Piperidines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate | 2001 |